Improved treatment of colorectal cancer with CF10 diversity supplement

Ended Project Grant Awarded Last action

Award ID
R41CA254834
Recipient
Awarding agency
Obligated
$500,917

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Place of performance
Yadkinville, NC 27055, USA

Award details come from USAspending.gov.

Description

Abstract
For supplement to CA254834 this minority administrative supplement to CA254834 requests funds for training charles chidi okechukwu in the translational objectives of the phase 1 sttr project and developing new business development and entrepreneurial skills fir the candidate that will support company growth. The funded phase 1 sttr project (CA254834) focuses on demonstrating that a novel FP polymer, CF10, displays improved activity in pre-clinical models of metastatic colorectal cancer (MCRC). Currently funded aims are: I) demonstrate CF10 inhibits CRC metastatic progression in an orthotopic colon tumor model; ad II) demonstrate improved anti-metastatic activity for CF10 in a RAT syngeneic CRC liver met model. With supplement funding, charles will investigate if CF10 will be effective in treating CRC with acquired resistance to 5-FU and will be potentiated in combination with leucovorin (LV; folinic acid), which complements ongoing studies. The supplemental aims are: S1) demonstrate improved anti-metastatic activity for CF10 in 5-FU-resistant orthotopic CRC models; and S2) evaluate leucovorin potentiation of CF10 in 5-FU-resistant orthotopic CRC models. The mentoring plan for charles will include training in technical skills related to pre-clinical drug development, translational research, and entrepreneurship. Training will include interfacing with researchers, clinical experts, and with business development experts. Charles will also receive mentoring in writing skills, including business plan development, and presentation skills, including presentation to investors. Training will enhance the long-term career opportunities of the applicant, including development of a professional network, and advance the goals of the company in commercializing CF10 technology.

Transactions

Action Obligated Date
Amendment Improved treatment of colorectal cancer with CF10 $0
Amendment $104,488
Original award $396,429

Quick answers

Who received award R41CA254834?

R41CA254834 was awarded to Deep Creek Pharma LLC by National Cancer Institute (National Institutes of Health) on August 17, 2021.

How much is award R41CA254834 worth?

$500,917 has been obligated on R41CA254834.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award